Want to see AU:EVE full AI Analyst Report?
Top Page
EVE Health Group Limited
(Sydney:EVE)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.01
▼(-30.00% Downside)
Action:Reiterated
Date:09/18/26
The score is primarily constrained by weak financial performance, driven by ongoing losses, negative margins, declining revenue, and persistent negative free cash flow despite a low-debt balance sheet. Technical signals are mixed but generally soft with the price below key moving averages. Valuation offers limited support given the negative P/E and lack of dividend.
Positive Factors
Very low leverage
A largely debt-free balance sheet reduces refinancing and interest-rate exposure, preserving financial flexibility while the company restructures. Positive equity also provides a buffer against operating volatility, although this benefit depends on containing losses and avoiding further dilution.
Negative Factors
Persistent unprofitability
Continued operating and net losses show that the current revenue base does not cover the company’s cost structure. Negative gross profit in the latest period is especially concerning because it indicates pressure before operating expenses, making a durable return to profitability harder.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
A largely debt-free balance sheet reduces refinancing and interest-rate exposure, preserving financial flexibility while the company restructures. Positive equity also provides a buffer against operating volatility, although this benefit depends on containing losses and avoiding further dilution.
Read all positive factors
EVE Health Group Limited (EVE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$5.28M
Dividend YieldN/A
Average Volume (3M)214.19K
Price to Earnings (P/E)―
Beta (1Y)0.25
Revenue Growth-33.53%
EPS Growth42.98%
CountryAU
Employees3
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding352,326,600
10 Day Avg. Volume163,183
30 Day Avg. Volume214,191
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.40
Price to Sales (P/S)4.80
P/FCF Ratio-3.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
EVE Health Group Limited Business Overview & Revenue Model
Company Description
Based in Subiaco, Australia, Eve Health Group Limited, originally incorporated in 2003 as EVE Investments Limited, is an international provider of health, wellness, and nutritional products. The company operates across Australia, New Zealand, the ...
How the Company Makes Money
EVE primarily makes money by selling its branded health products, generating revenue from product sales through retail, pharmacy, and other distribution channels (including wholesale/distributor arrangements where applicable). Key revenue streams ...
EVE Health Group Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
21
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.15M | 1.73M | 2.13M | 2.33M | 2.01M |
| Gross Profit | -106.51K | 824.03K | 876.96K | 827.83K | -1.00M |
| EBITDA | -1.77M | -1.43M | -1.51M | -2.18M | -4.53M |
| Net Income | -1.89M | -1.58M | -1.90M | -4.04M | -5.37M |
Balance Sheet | |||||
| Total Assets | 4.28M | 4.12M | 2.52M | 4.13M | 8.07M |
| Cash, Cash Equivalents and Short-Term Investments | 1.24M | 903.42K | 106.17K | 192.48K | 1.10M |
| Total Debt | 0.00 | 91.28K | 74.85K | 4.28K | 492.39K |
| Total Liabilities | 330.02K | 572.45K | 1.30M | 1.01M | 1.14M |
| Stockholders Equity | 3.95M | 3.55M | 1.22M | 3.12M | 6.93M |
Cash Flow | |||||
| Free Cash Flow | -1.74M | -1.62M | -1.11M | -1.65M | -3.80M |
| Operating Cash Flow | -1.74M | -1.62M | -1.11M | -1.65M | -3.77M |
| Investing Cash Flow | -1.90K | 2.13M | 874.27K | 498.46K | -26.05K |
| Financing Cash Flow | 2.08M | 279.09K | 146.37K | 240.69K | 1.74M |
EVE Health Group Limited Technical Analysis
Positive
0.02
Price Trends
0.02
Positive
0.02
Positive
0.02
Negative
Market Momentum
>-0.01
Positive
52.08
Neutral
300.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EVE, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 52.08 is Neutral, neither overbought nor oversold. The STOCH value of 300.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:EVE.
EVE Health Group Limited Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
46 Neutral | AU$13.33M | -1.79 | -88.51% | ― | 11.96% | -81.99% | |
43 Neutral | AU$5.28M | -2.34 | -49.07% | ― | -33.53% | 42.98% | |
43 Neutral | AU$13.39M | -4.21 | -12.90% | ― | 0.46% | 46.48% | |
39 Underperform | AU$15.82M | -5.75 | 1795.70% | ― | 0.72% | -486.96% | |
39 Underperform | AU$19.28M | -0.01 | -130.72% | ― | -33.05% | 94.22% |
* Consumer Defensive Sector Average
AU:EVE
EVE Health Group Limited
0.02
-0.03
-62.50%
AU:AHF
Australian Dairy Nutritionals Group
0.02
-0.02
-56.41%
AU:NUC
Nuchev Pty Ltd
0.09
-0.05
-37.04%
AU:HCT
Holista Colltech Limited
0.04
-0.04
-49.41%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
0.00
0.00%
EVE Health Group Limited Corporate Events
EVE Health Director Updates ASX on Lapse of Performance-Based Options
Oct 5, 2026
EVE Health Group Limited has reported a change in the security holdings of director Stuart Gunzburg, detailing adjustments to both his direct and indirect interests in the company. The disclosure notes that Gunzburg maintains significant ordinary ...
EVE Health Group Trims Future Dilution as 1.0m Options Lapse
Oct 5, 2026
EVE Health Group Limited has disclosed a change in its issued capital, notifying the cessation of a series of options listed on the ASX. The options, trading under the code EVEAI and exercisable at $0.06 by December 31, 2028, relate to the company...
EVE Health Sets November 2026 AGM as It Advances Vertically Integrated Pharma Platform
Sep 22, 2026
EVE Health Group Limited, an Australian life sciences company, develops and commercialises pharmaceutical products targeting high-growth therapeutic areas such as women’s reproductive health and men’s sexual health. Its lead assets, Dy...
EVE Health Group Targets Growth in Reformulated Generic Medicines
Sep 21, 2026
EVE Health Group has outlined its strategy to build a commercial-stage pharmaceutical reformulation business targeting established generic medicines that are hard to swallow, inconsistently effective or burdensome in combination therapy. By focusi...
EVE Health Group to Release 2.25 Million Shares from Escrow
Sep 3, 2026
EVE Health Group Limited has notified investors that 2,250,000 fully paid ordinary shares will be released from escrow on 9 September 2026 in line with ASX Listing Rule 3.10A. The shares were originally issued in May 2026 as consideration under a ...
EVE Health Group files ASX governance key for FY2026
Aug 31, 2026
EVE Health Group Limited has lodged its annual Appendix 4G with the ASX, detailing how it complies with the ASX Corporate Governance Council’s principles and recommendations. The company’s corporate governance statement for the year en...
EVE Health Group Posts Wider Loss as Revenue Slides in 2026
Aug 31, 2026
EVE Health Group reported a sharp deterioration in financial performance for the year ended 30 June 2026, with revenue from ordinary activities falling 33.53% to $1.15 million compared with the prior year. The loss after tax from continuing operat...
EVE Health Advances Libbo Clinical Program and Hits Apixaban Milestone Amid CEO Transition
Aug 7, 2026
EVE Health Group reported progress on its Libbo erectile dysfunction program, finalising the pilot clinical study protocol and engaging a contract research organisation and clinical site to compare its vardenafil oral soluble film with an approved...
EVE Health advances Libbo clinical program and apixaban reformulation as new CEO targets commercial growth
Jul 31, 2026
EVE Health Group has advanced its clinical and technology pipeline in the June quarter, finalising the protocol and engaging a contract research organisation and clinical site for the Libbo pilot study, which will compare its vardenafil oral solub...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.